Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Norris Perne & French LLP MI

Norris Perne & French LLP MI reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 128,630 shares of the medical research company’s stock after selling 3,363 shares during the quarter. Charles River Laboratories International comprises about 2.5% of Norris Perne & French LLP MI’s portfolio, making the stock its 9th biggest position. Norris Perne & French LLP MI owned approximately 0.25% of Charles River Laboratories International worth $34,852,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new position in Charles River Laboratories International in the 4th quarter valued at about $101,319,000. Point72 Asset Management L.P. boosted its position in shares of Charles River Laboratories International by 499.1% during the fourth quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock valued at $87,228,000 after buying an additional 307,398 shares during the last quarter. Meritage Group LP grew its holdings in Charles River Laboratories International by 30.8% during the fourth quarter. Meritage Group LP now owns 1,155,376 shares of the medical research company’s stock worth $273,131,000 after buying an additional 271,743 shares in the last quarter. KBC Group NV raised its position in Charles River Laboratories International by 5,003.9% in the 4th quarter. KBC Group NV now owns 215,639 shares of the medical research company’s stock valued at $50,977,000 after buying an additional 211,414 shares during the last quarter. Finally, Armistice Capital LLC bought a new position in Charles River Laboratories International during the 3rd quarter valued at $30,573,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL traded down $0.77 during trading on Friday, reaching $206.58. 666,758 shares of the company were exchanged, compared to its average volume of 479,353. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The company’s 50-day moving average is $220.16 and its two-hundred day moving average is $232.48. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. The company has a market cap of $10.64 billion, a price-to-earnings ratio of 24.30, a P/E/G ratio of 1.96 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. Research analysts forecast that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the subject of several recent analyst reports. Argus reiterated a “hold” rating on shares of Charles River Laboratories International in a research note on Friday. The Goldman Sachs Group began coverage on Charles River Laboratories International in a research report on Thursday, June 6th. They issued a “buy” rating and a $290.00 price objective on the stock. Mizuho began coverage on Charles River Laboratories International in a research note on Friday, June 7th. They issued a “neutral” rating and a $235.00 price objective for the company. Barclays initiated coverage on Charles River Laboratories International in a research note on Friday. They set an “equal weight” rating and a $230.00 target price on the stock. Finally, TD Cowen reduced their price target on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research report on Monday, May 13th. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $254.50.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).